Aristotle Atlantic Partners LLC Has $15.62 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Aristotle Atlantic Partners LLC decreased its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 6.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 95,852 shares of the company's stock after selling 6,075 shares during the quarter. Aristotle Atlantic Partners LLC's holdings in Zoetis were worth $15,617,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in ZTS. Callahan Advisors LLC grew its position in Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock valued at $2,135,000 after acquiring an additional 6,221 shares in the last quarter. CIBC Asset Management Inc grew its holdings in shares of Zoetis by 24.1% in the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock valued at $38,617,000 after purchasing an additional 46,050 shares in the last quarter. Pensionfund Sabic increased its stake in Zoetis by 55.6% during the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company's stock worth $1,825,000 after buying an additional 4,000 shares during the period. Schroder Investment Management Group lifted its holdings in Zoetis by 2.6% during the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock worth $40,036,000 after buying an additional 6,169 shares in the last quarter. Finally, PFW Advisors LLC purchased a new position in Zoetis in the 4th quarter valued at approximately $1,764,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Down 5.2 %

Shares of NYSE ZTS traded down $8.24 during midday trading on Tuesday, reaching $149.82. 4,122,056 shares of the company's stock were exchanged, compared to its average volume of 2,474,559. The stock has a market capitalization of $66.85 billion, a PE ratio of 27.39, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The business's fifty day moving average price is $158.17 and its two-hundred day moving average price is $166.80. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company's revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.38 EPS. Analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.33%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is 36.56%.

Insider Transactions at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares of the company's stock, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,862 shares of company stock worth $312,254. Insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ZTS. Morgan Stanley lowered their target price on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Piper Sandler upped their target price on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a report on Thursday, February 27th. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Barclays lifted their price target on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Finally, Stifel Nicolaus reduced their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research report on Monday, April 14th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $214.40.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.